RxDoctor Payments Data

Yelin Yang, MD

Internal Medicine · Scranton, PANPI 1225477250

Payments from drug & device makers

$3,192in general payments, 2019–2025

Across 192 payments — averaging $16.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$695
  • AstraZeneca$451
  • Lilly USA, LLC$291
  • Pfizer$201
  • Johnson & Johnson$113
  • plus $429 from 13 others

What the payments were for

  • Food & beverage$3,17299%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,192 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$46,372
Medicare patients
123
Services billed
554

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin74$65,820
OzempicSemaglutide61$58,041
EliquisApixaban53$35,382
JanuviaSitagliptin Phosphate37$31,639
FarxigaDapagliflozin Propanediol24$27,831
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$20,658
TrulicityDulaglutide21$20,421
XareltoRivaroxaban17$11,094
Breo ElliptaFluticasone/Vilanterol16$9,343
SymbicortBudesonide/Formoterol Fumarate27$6,470
TradjentaLinagliptin12$6,069
Novolog FlexpenInsulin Aspart17$5,048
Atorvastatin Calcium412$4,967
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate19$3,470
Varenicline Tartrate19$3,257

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$38$71,88886 claims
Novo NordiskOzempic$1,012$58,04161 claims
PfizerEliquis$201$35,38253 claims
AstraZenecaFarxiga, Symbicort$451$34,30051 claims
MerckJanuvia$30$31,63937 claims
GSKTrelegy Ellipta, Breo Ellipta$52$30,00148 claims
Lilly USA, LLCTrulicity$291$20,42121 claims
Johnson & JohnsonXarelto$113$11,09417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Scranton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →